Jia Wang

Key Laboratory Of Carcinogenesis And Translational Research
Beijing, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 57 publications

Icotinib plus chemotherapy as neoadjuvant treatment for resectable stage II-IIIB EGFR-mutant lung adenocarcinoma: a phase II study (NEOIPOWER).

Icotinib plus chemotherapy as neoadjuvant treatment for resectable stage II-IIIB EGFR-mutant lung adenocarcinoma: a phase II study (NEOIPOWER).

Journal: Lung cancer (Amsterdam, Netherlands)

Published: March 25, 2025

Lactate production by tumor-resident Staphylococcus promotes metastatic colonization in lung adenocarcinoma.

Lactate production by tumor-resident Staphylococcus promotes metastatic colonization in lung adenocarcinoma.

Journal: Cell host & microbe

Published: November 10, 2024

The role of dynamic monitoring of plasma cell-free DNA methylation in predicting pathological response in resectable stage IIB-IIIB non-small cell lung cancer: biomarker analyses from a prospective phase II trial.

The role of dynamic monitoring of plasma cell-free DNA methylation in predicting pathological response in resectable stage IIB-IIIB non-small cell lung cancer: biomarker analyses from a prospective phase II trial.

Journal: BMC medicine

Published: October 27, 2024

Early Hints of Metagenome Next-Generation Sequencing and Copy Number Variations Analysis: An Occult Case of Leptomeningeal Metastasis With Rapid Cognitive Decline.

Early Hints of Metagenome Next-Generation Sequencing and Copy Number Variations Analysis: An Occult Case of Leptomeningeal Metastasis With Rapid Cognitive Decline.

Journal: Clinical case reports

Published: July 27, 2024

MMsurv: a multimodal multi-instance multi-cancer survival prediction model integrating pathological images, clinical information, and sequencing data.

MMsurv: a multimodal multi-instance multi-cancer survival prediction model integrating pathological images, clinical information, and sequencing data.

Journal: Briefings in bioinformatics

Published: June 26, 2024

Access to radiotherapy in improving gastric cancer care quality and equality.

Access to radiotherapy in improving gastric cancer care quality and equality.

Journal: Communications medicine

Published: February 05, 2024

Burden of liver cancer attributable to high fasting plasma glucose: a global analysis based on the global burden of disease study 2019.

Burden of liver cancer attributable to high fasting plasma glucose: a global analysis based on the global burden of disease study 2019.

Journal: The journal of nutrition, health & aging

Published: November 02, 2023

Nanodrugs systems for therapy and diagnosis of esophageal cancer.

Nanodrugs systems for therapy and diagnosis of esophageal cancer.

Journal: Frontiers in bioengineering and biotechnology

Published: June 02, 2023

Global, regional, and national burden of tracheal, bronchus, and lung cancers attributable to high fasting plasma glucose: A systematic analysis of global burden of disease 2019.

Global, regional, and national burden of tracheal, bronchus, and lung cancers attributable to high fasting plasma glucose: A systematic analysis of global burden of disease 2019.

Journal: Journal of diabetes

Published: May 25, 2023

Efficacy and safety of adjuvant EGFR TKI alone and in combination with chemotherapy for resected EGFR mutation-positive non-small cell lung cancer: A Bayesian network meta-analysis.

Efficacy and safety of adjuvant EGFR TKI alone and in combination with chemotherapy for resected EGFR mutation-positive non-small cell lung cancer: A Bayesian network meta-analysis.

Journal: Critical reviews in oncology/hematology

Published: March 15, 2023

Global burden of hepatitis B attributable to modifiable risk factors from 1990 to 2019: a growing contribution and its association with socioeconomic status.

Global burden of hepatitis B attributable to modifiable risk factors from 1990 to 2019: a growing contribution and its association with socioeconomic status.

Journal: Globalization and health

Published: December 23, 2022

Osimertinib as neoadjuvant therapy in patients with EGFR-mutant resectable stage II-IIIB lung adenocarcinoma (NEOS): A multicenter, single-arm, open-label phase 2b trial.

Osimertinib as neoadjuvant therapy in patients with EGFR-mutant resectable stage II-IIIB lung adenocarcinoma (NEOS): A multicenter, single-arm, open-label phase 2b trial.

Journal: Lung cancer (Amsterdam, Netherlands)

Published: November 03, 2022

Showing 1-12 of 57

Last Updated: 09/26/2026